HIV-1 Drug Resistance Among Treatment-Naive Transgenders from India

被引:0
作者
Kurle, Swarali N. [1 ]
Kandaswami, Sudarshan [2 ]
Gadhe, Sharda [1 ]
Patil, Ajit [1 ]
Sarkar, Rohit [2 ]
Mehta, Sonal [2 ]
Gangakhedkar, Raman [3 ]
Arumugam, Viswanathan [2 ]
Chawla, Umesh [2 ]
机构
[1] ICMR Natl AIDS Res Inst, HIV Drug Resistance Lab, 73 G Block, Pune 411026, Maharashtra, India
[2] India HIV AIDS Alliance, New Delhi, India
[3] Indian Council Med Res, New Delhi, India
关键词
transgender; HIV-1; primary drug resistance; India; VIRUS TYPE-1 PROTEASE; REVERSE-TRANSCRIPTASE; MUTATIONS; IMPACT;
D O I
10.1089/aid.2021.0157
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Transgenders (TGs) are highly affected by HIV with high prevalence of 3.14% in India. Since 2017, targeted preventive efforts have been initiated by the government and HIV-infected TGs are being provided the antiretroviral (ART) treatment. Information on the primary HIV drug resistance is crucial for appropriate treatment selection to curb further spread of HIV in this population. In this study, we analyzed HIV-1 pol gene sequences from 36 TGs for presence of drug resistance mutations. To our knowledge, this first study from India reports high-level primary drug resistance (13.8%) among the TG population. Mutations M184V, A98G, K103N, G190A, and Y318F associated with resistance to nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitors were observed. All pol gene sequences revealed HIV-1 subtype C in all study TG. High-level HIV-1 drug resistance warrant nationwide larger studies on TGs to understand the level of primary ART drug resistance among this population.
引用
收藏
页码:990 / 993
页数:4
相关论文
共 15 条
[1]   Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy [J].
Bacheler, L ;
Jeffrey, S ;
Hanna, G ;
D'Aquila, R ;
Wallace, L ;
Logue, K ;
Cordova, B ;
Hertogs, K ;
Larder, B ;
Buckery, R ;
Baker, D ;
Gallagher, K ;
Scarnati, H ;
Tritch, R ;
Rizzo, C .
JOURNAL OF VIROLOGY, 2001, 75 (11) :4999-5008
[2]   Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors [J].
Basson, Adriaan E. ;
Rhee, Soo-Yon ;
Parry, Chris M. ;
El-Khatib, Ziad ;
Charalambous, Salome ;
de Oliveira, Tulio ;
Pillay, Deenan ;
Hoffmann, Christopher ;
Katzenstein, David ;
Shafer, Robert W. ;
Morris, Lynn .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) :960-971
[3]   Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors [J].
Harrigan, PR ;
Mo, T ;
Wynhoven, B ;
Hirsch, J ;
Brumme, Z ;
McKenna, P ;
Pattery, T ;
Vingerhoets, J ;
Bacheler, LT .
AIDS, 2005, 19 (06) :549-554
[4]   Impact of HIV-1 pol diversity on drug resistance and its clinical implications [J].
Kantor, Rami .
CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (06) :594-606
[5]   Surveillance of HIV drug resistance transmission in Iran: experience gained from a pilot study [J].
Mousavi, Seyed Mohsen ;
Hamkar, Rasool ;
Gouya, Mohammad Mehdi ;
Safaie, Afshin ;
Zahraei, Seyed Mohsen ;
Yazdani, Zinab ;
Namini, Somayeh Asbaghi ;
Bertagnolio, Silvia ;
Sutherland, Donald ;
Sandstrom, Paul ;
Brooks, James .
ARCHIVES OF VIROLOGY, 2010, 155 (03) :329-334
[6]  
NACO, 2018, OP GUID CAR SUPP CTR
[7]  
NACO, 2018, IND HIV EST 2017 TEC
[8]  
National Aids Control Organization (NACO), 2019, ANN REP 2018 2019
[9]   Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing [J].
Rhee, SY ;
Liu, T ;
Ravela, J ;
Gonzales, MJ ;
Shafer, RW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3122-3126
[10]   Evolution of HIV-1 in India [J].
Seth, Pradeep .
INDIAN JOURNAL OF VIROLOGY, 2010, 21 (01) :3-7